This is a preview of subscription content, log in via an institution to check access.
Notes
2016 euros
Reference
Casado LF, et al. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. ClinicoEconomics and Outcomes Research 2016: 475-484, No. 8, 21 Sep 2016. Available from: URL: https://dx.doi.org/10.2147/CEOR.S114524
Rights and permissions
About this article
Cite this article
Obinutuzumab plus chlorambucil cost effective for CLL in Spain. PharmacoEcon Outcomes News 763, 27 (2016). https://doi.org/10.1007/s40274-016-3440-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3440-3